ReviewClinical science (London, England : 1979)2025
The role of relaxins in blood cell modulation: interactions with relaxin family peptide receptor 1 (RXFP1) and glucocorticoid receptor (GR).
Review in Clinical science (London, England : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Description of a Large Family with Periodic Fever Carrying a Variant inInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relaxin family functions as pleiotropic hormones with various antioxidant, angiogenic, anti-apoptotic, anti-hypertrophic, anti-inflammatory, antifibrotic, and vasodilatory effects. To fully appreciate the potential therapeutic applications of relaxins and the pathophysiological implications, it is important to understand their multifaceted roles. This comprehensive review of current literature aims to elucidate the role of relaxins in modulating the biology and function of blood cells. It places special emphasis on the signaling pathways of relaxin family peptide receptor 1 (RXFP1) and the glucocorticoid receptor (GR) activated by relaxin-2. Relaxin-2 influences circulating blood cell counts and exerts inhibitory effects on megakaryocytes, thrombocytes, and mast cells. It also possesses immunomodulatory characteristics that affect granulocytes and agranulocytes, particularly regarding their morphology, differentiation, and function. Relaxin-1 regulates dendritic cell maturation and cytokine secretion. RXFP1 could play significant roles in blood malignancies and preeclampsia. The broad spectrum of activities demonstrated by relaxins significantly influences blood cell biology and highlights their therapeutic potential in a range of conditions, including hematological, cardiovascular, renal, pregnancy-related, and fibrotic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.